Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.
ABSTRACT Endogenous antimicrobial peptides of the cathelicidin family contribute to innate immunity. The emergence of widespread antibiotic resistance in many commonly encountered bacteria requires the search for new bactericidal agents with therapeutic potential. Solid-phase synthesis was employed to prepare linear antimicrobial peptides found in cathelicidins of five mammals: human (FALL39/LL37), rabbit (CAP18), mouse (mCRAMP), rat (rCRAMP), and sheep (SMAP29 and SMAP34). These peptides were tested at ionic strengths of 25 and 175 mM against Pseudomonas aeruginosa , Escherichia coli , Staphylococcus aureus , and methicillin-resistant Staphylococcus aureus . Each peptide manifested activity against P. aeruginosa irrespective of the NaCl concentration. CAP18 and SMAP29 were the most effective peptides of the group against all test organisms under both low- and high-salt conditions. Select peptides of 15 to 21 residues, modeled on CAP18 (37 residues), retained activity against the gram-negative bacteria and methicillin-sensitive S. aureus , although the bactericidal activity was reduced compared to that of the parent peptide. In accordance with the behavior of the parent molecule, the truncated peptides adopted an α-helical structure in the presence of trifluoroethanol or lipopolysaccharide. The relationship between the bactericidal activity and several physiochemical properties of the cathelicidins was examined. The activities of the full-length peptides correlated positively with a predicted gradient of hydrophobicity along the peptide backbone and with net positive charge; they correlated inversely with relative abundance of anionic residues. The salt-resistant, antimicrobial properties of CAP18 and SMAP29 suggest that these peptides or congeneric structures have potential for the treatment of bacterial infections in normal and immunocompromised persons and individuals with cystic fibrosis.
Article Figures and data Abstract Introduction Results Discussion Materials and methods References Decision letter Author response Article and author information Metrics Abstract The synthesis of cholesterol and fatty acids (FA) in the liver is independently regulated by SREBP-2 and SREBP-1c, respectively. Here, we genetically deleted Srebf-2 from hepatocytes and confirmed that SREBP-2 regulates all genes involved in cholesterol biosynthesis, the LDL receptor, and PCSK9; a secreted protein that degrades LDL receptors in the liver. Surprisingly, we found that elimination of Srebf-2 in hepatocytes of mice also markedly reduced SREBP-1c and the expression of all genes involved in FA and triglyceride synthesis that are normally regulated by SREBP-1c. The nuclear receptor LXR is necessary for Srebf-1c transcription. The deletion of Srebf-2 and subsequent lower sterol synthesis in hepatocytes eliminated the production of an endogenous sterol ligand required for LXR activity and SREBP-1c expression. These studies demonstrate that cholesterol and FA synthesis in hepatocytes are coupled and that flux through the cholesterol biosynthetic pathway is required for the maximal SREBP-1c expression and high rates of FA synthesis. https://doi.org/10.7554/eLife.25015.001 Introduction Cholesterol and fatty acid (FA) biosynthetic gene expression is regulated by the sterol regulatory element-binding protein (SREBP) family of transcription factors (Horton et al., 2002). The three family members—SREBP-1a, SREBP-1c, and SREBP-2—are basic-helix-loop helix transcription factors that bind to sterol response elements of promoters to activate transcription. SREBP-1a and SREBP-1c are encoded by the same gene but have independent promoters that utilize a unique first exon. SREBP-2 is encoded by a separate gene. The membrane-bound, inactive forms of SREBPs are located in the endoplasmic reticulum bound to Scap, an escort protein that serves as a sensor of cellular sterol levels (Brown and Goldstein, 2009). When cellular sterol levels are high, Scap binds an ER retention protein, Insig, which retains the SREBP/Scap complex in the ER. To generate the active nuclear form of SREBPs, SREBP/Scap dissociates from Insig, and the complex moves from the ER to the Golgi where two proteases, designated S1P and S2P, sequentially cleave SREBPs releasing the amino-terminal fragment, which travels to the nucleus to activate regulated genes. The in vivo transcriptional-activating properties of each SREBP isoform have been investigated through the generation and characterization of transgenic and knockout mice (Horton et al., 2002). In most tissues, the predominant SREBP-1 isoform expressed is SREBP-1c (Shimomura et al., 1997). Overexpression of nuclear SREBP-1c (nSREBP-1c) in livers of mice resulted in the transcriptional activation of genes involved in FA and triglyceride (TG) synthesis (Horton et al., 2002). As a consequence of increased de novo lipogenesis, mice expressing nSREBP-1c developed fatty livers. Consistent with the role of SREBP-1c in activating lipogenesis, SREBP-1c is activated in the liver by insulin through a partially defined pathway that involves the insulin receptor, Akt, and mTORC1 (Owen et al., 2012). Conversely, genetic deletion of Srebf-1c led to a selective reduction in the expression of genes involved in FA and TG synthesis (Liang et al., 2002). The SREBP-1a isoform is a more potent transcription activator than SREBP-1c, owing to its longer transactivation domain (Horton et al., 2002). Overexpression of the minor nSREBP-1a isoform in mouse liver led to the activation of genes involved in both FA and cholesterol biosynthesis; resulting in the accumulation of both cholesterol and TGs in liver (Horton et al., 2002). In stark contrast, the selective deletion of Srebf-1a reduced the expression of only acetyl-CoA carboxylase (ACC) 2 in the liver, one of the two ACC isoforms that carry out the first committed enzymatic step in FA synthesis (Im et al., 2009). The genetic ablation of both Srebf-1a and Srebf-1c resulted in significant, but incomplete, embryonic lethality (Horton et al., 2002). In those few Srebf-1a/Srebf-1c knockout mice that survived to adulthood, the gene expression profile in the liver was similar to that observed in livers from mice that had the genetic ablation of only the Srebf-1c isoform. Transgenic overexpression of nSREBP-2 in liver led to the preferential activation of genes involved in cholesterol biosynthesis, the LDL receptor (LDLR), and PCSK9 (Horton et al., 2003). However, nSREBP-2 overexpression also increased the mRNA levels of FA biosynthetic genes, albeit to a lesser extent than those involved in cholesterol synthesis. To further delineate genes specifically regulated by SREBP-2, we initially attempted to obtain mice with homozygous germ-line deletions of Srebf-2 using a traditional gene-replacement approach. Crosses of Srebf-2+/-mice did not produce viable offspring homozygous for the disrupted Srebf-2 allele. Most embryos homozygous for the disrupted Srebf-2 allele appeared to die between day 7–8 post-coitum, but the cause of this embryonic lethality was not investigated (Horton et al., 2002). Mice that were heterozygous for the germ-line deletion of Srebf-2 had no discernable phenotype. To bypass the embryonic lethality, here we used albumin-driven, Cre-mediated recombination to delete Srebf-2 in hepatocytes of mice. The results confirm that SREBP2 is required for normal levels of cholesterol biosynthetic gene expression, but unexpectedly, we found the expression of Srebf-1c and its target genes for FA and TG synthesis was also dependent on SREBP-2 expression. The absence of SREBP-2 lead to reduced LXR activity, which explained the loss of SREBP-1c expression, possibly owing to the loss of an endogenous sterol ligand that is dependent on flux through the cholesterol biosynthesis pathway. Results The vector and targeting strategy used to conditionally disrupt Srebf-2 is shown in Figure 1A and B. Mice homozygous for the floxed Srebf-2 allele, were bred to transgenic mice that express Cre recombinase driven by the albumin promoter to obtain hepatocyte-specific gene deletion (hepatocyte-Srebf-2-/-). Littermates bearing two floxed Srebf-2 alleles with no albumin-cre were designated as wild type controls. Hepatocyte -Srebf-2-/- mice weighed slightly less than littermate controls but liver weights were unchanged (Table 1). In the absence of SREBP-2, plasma and liver cholesterol concentrations were reduced by 68% and 20%, respectively. Unexpectedly, plasma and liver TGs were also reduced by 50% and 76%, in hepatocyte -Srebf-2-/- mice (Table 1). Figure 1 Download asset Open asset Gene-targeting strategy and characterization of the floxed Srebf-2 allele. (A) Schematic of gene-targeting strategy. Cre-mediated excision of the sequences flanked by the loxP sites deletes 660 bp of the Srebf-2 promoter and exon 1, which includes the initiator methionine and residues encoding the NH2-terminal domain of Srebf-2. The positions of primers (P1 and P2, P3 and P4) used for PCR detection of homologous recombination are denoted by arrowheads. (B) Genotype analysis of the conditionally targeted Srebf-2 mice by PCR of tail-derived DNA. (C) Levels of proteins in the livers of WT and hepatocyte-Srebf-2-/- mice. Nuclear and membrane protein was made from each mouse liver described in Table 1 and equal aliquots from each were pooled (total, 30 µg) and subjected to SDS-PAGE and immunoblot analysis was carried out for the indicated protein as described in 'Materials and methods.' The precursor and nuclear form of SREBPs were denoted as P and N, respectively. https://doi.org/10.7554/eLife.25015.002 Table 1 Phenotypic comparison of WT and hepatocyte-Srebf-2-/- mice. Male mice 12–13 wks of age fed chow ad lib were sacrificed and blood and tissues obtained. Each value represents mean ± SEM. https://doi.org/10.7554/eLife.25015.003 ParametersWTSrebf-2-/-Number of mice66Body weight (g)33.1 ± 1.027.7 ± 1.0*Liver weight (g)1.32 ± 0.131.28 ± 0.09Plasma cholesterol (mg/dl)104 ± 12.333.7 ± 6.6*Plasma TGs (mg/dl)94.8 ± 12.547.7 ± 1. 4*Liver cholesterol (mg/g)2.21 ± 0.081.78 ± 0.06*Liver TGs (mg/g)12.4 ± 3.092.98 ± 0.72* *Denotes the level of statistical significance of p<0.05 (Student's t test) between WT and hepatocyte-Srebf-2-/- mice. Immunoblot analyses of SREBPs from livers of mice described in Table 1 are shown in Figure 1C. As expected, the precursor (P) and nSREBP-2 (N) protein were undetectable in hepatocyte-Srebf-2-/- livers. However, the SREBP-1 precursor and nuclear protein levels were also reduced by ~90% in hepatocyte-Srebf-2-/- livers. Calnexin and CREB were used as controls for membrane and nuclear proteins, respectively. Figure 2 shows the results of quantitative PCR assays that measured mRNA levels of lipid metabolism related genes in livers of mice described in Table 1. The mRNA levels of SREBP-2-regulated genes involved in cholesterol biosynthesis and uptake (HMG-CoA synthase, HMG-CoA reductase, farnesyl diphosphate synthase, squalene synthase, and PCSK9) were reduced by 60–80% in hepatocyte-Srebf-2-/- livers compared to controls. The mRNA for the LDLR was only reduced by 20%. SREBP-1c mRNA levels also were 90% lower than that measured in livers of wild type (WT) mice, while SREBP-1a mRNA levels remained unchanged. SREBP-1c-regulated genes in the FA biosynthetic pathway (ACC1), fatty acid synthase (FAS), ELOVL6, and stearoyl-CoA desaturase-1 (SCD1)) were reduced ~50 to>95% in hepatocyte-Srebf-2-/- livers; however, ACC2 expression, which is primarily regulated by SREBP-1a (Im et al., 2009), was only slightly lower. Srebf-1c transcription is regulated by LXR and by nSREBP-1c itself through a feed-forward loop (Repa et al., 2000). SREBP-1c mRNA levels were reduced by 90%, which explains the loss of SREBP-1 protein in hepatocyte-Srebf-2-/- livers. The mRNA levels of LXRα and β were unchanged but the mRNA levels of additional LXR-regulated genes, ABCG5 and ABCG8, were reduced by 60–70% (Supplementary file 2), suggesting that LXR activity was lower in the absence of SREBP-2. Figure 2 Download asset Open asset Levels of mRNAs in livers of WT and hepatocyte-Srebf-2-/- mice. Total RNA from livers of each mouse liver described in Table 1 was subjected to real-time RT-PCR as described in 'Materials and methods.' Apo B was used as the invariant control. Values represent the amount of mRNA relative to those in the wild-type mice, which are arbitrarily assigned a value of 1. (A) Genes involved in cholesterol homeostasis. (B) Genes involved in FA homeostasis. https://doi.org/10.7554/eLife.25015.004 To confirm that the reduced expression of cholesterol and FA synthesis genes in hepatocyte-Srebf-2-/- livers translated into lower rates of lipid synthesis, we measured the incorporation of tritiated water into newly synthesized sterols and FAs. In hepatocyte-Srebf-2-/- livers, rates of sterol and FA synthesis were decreased by 59% and 68%, respectively (Figure 3). Figure 3 Download asset Open asset In vivo sterol and FA synthesis rates in livers of WT and hepatocyte-Srebf-2-/- mice. Six 4-month-old male WT and hepatocyte-Srebf-2-/- mice were injected intraperitoneally with 50 mCi 3H-labeled water and rates of hepatic sterol and FA synthesis were determined as described in 'Materials and methods'. https://doi.org/10.7554/eLife.25015.005 Inasmuch as the expression of LXRα and β were unaffected by deleting Srebf-2, we hypothesized that the loss of SREBP-1c expression and reduced FA synthesis in hepatocyte-Srebf-2-/- livers was due to the absence of a ligand for LXR that is either generated within or derived from the cholesterol biosynthetic pathway. To test this hypothesis, we first fed mice a synthetic ligand for LXR, T0901317. Administration of T0901317 to hepatocyte-Srebf-2-/- mice induced SREBP-1c mRNA and protein expression to levels similar to that measured in WT livers (Figure 4A,B). Increased SREBP-1c expression was associated with higher mRNA levels of ACC1 and FAS (Figure 4B). Inasmuch as LXR can independently transcriptionally activate the same FA synthesis genes, we verified that the induction of ACC1 and FAS was specifically due to SREBP-1c by feeding mice that lack all SREBPs as a result of the deletion of Scap the LXR agonist (Moon et al., 2012). Administration of T0901317 to mice with hepatocyte-specific deletion of Scap did not significantly change the mRNA levels of ACC1 or FAS (Figure 4—figure supplement 1). This suggests that LXR administration to the hepatocyte-Srebf-2-/- mice induced the mRNA levels of FA synthesis genes through the restoration of SREBP-1c expression and not through direct transcriptional activation by LXR. Figure 4 with 1 supplement see all Download asset Open asset Levels of mRNAs and proteins in the livers of WT and hepatocyte-Srebf-2-/-mice fed chow diet supplemented with an LXR agonist. Mice 7–11 weeks of age were fed ad libitum chow or chow supplemented with 25 mg/kg of a LXR agonist (T901317) for three weeks prior to study. (A) Liver membrane and nuclear extract protein was made from each mouse and equal aliquots were pooled (total, 30 µg) and subjected to SDS-PAGE and immunoblot analysis as described in 'Materials and methods.' The precursor and nuclear form of SREBPs are denoted as P and N, respectively. (B) Total RNA from each mouse liver was subjected to real-time RT-PCR as described in 'Materials and methods.' Apo B was used as the invariant control. Values represent the amount of mRNA relative to those in the WT mice, which are arbitrarily assigned a value of 1. The following figure supplements are available for Figure 4. https://doi.org/10.7554/eLife.25015.006 Cholesterol feeding leads to the production of oxysterols in the liver that can also activate LXR; therefore, we next fed mice diets supplemented with cholesterol to determine whether dietary cholesterol could restore SREBP-1c expression in hepatocyte-Srebf-2-/- livers. Dietary supplementation of 0.2% cholesterol increased liver cholesterol concentrations and SREBP-1c mRNA levels to that measured in WT mice fed chow (Figure 5A,C). As shown in Figure 5B, nSREBP-1c protein levels in hepatocyte-Srebf-2-/- livers were slightly lower than that in WT mice fed chow, but this was sufficient to restore the expression of mRNAs for FA biosynthetic genes to levels found in WT livers (Figure 5C). SREBP-2 regulated genes remained low and unaffected by cholesterol feeding (Figure 5C). Figure 5 Download asset Open asset Liver lipid concentrations, mRNA, and protein levels in WT and hepatocyte-Srebf-2-/- mice fed chow or chow supplemented with cholesterol. Mice 7–11 weeks of age were fed chow (n = 6–7) or chow supplemented with 0.2% cholesterol (n = 6–7) for six weeks prior to study. (A) Liver cholesterol and TG concentrations were measured as described in 'Materials and methods.' (B) Equal aliquots of nuclear and membrane protein from each mouse liver were pooled (total, 30 µg) and subjected to SDS-PAGE and immunoblot analysis for the indicated protein as described in 'Materials and methods.' The precursor and nuclear form of SREBPs were denoted as P and N, respectively. (C) Total RNA from the livers of each mouse was subjected to real-time RT-PCR as described in 'Materials and methods.' Apo B was used as the invariant control. Values represent the amount of mRNA relative to those in WT mice, which are arbitrarily assigned a value of 1. * denotes a level of statistical significance of p<0.05 (Student's t test) between WT and hepatic-Srebf-2-/-mice, ND denotes no significant difference between the indicated groups. https://doi.org/10.7554/eLife.25015.008 To identify the potential missing LXR ligand in hepatocyte-Srebf-2-/- mice, we performed LC-MS/MS to quantify the cholesterol biosynthetic intermediates and oxysterol concentrations in the liver. As shown in Supplementary file 1, the concentrations of intermediates in the cholesterol biosynthetic pathway were not consistently changed or slightly higher in livers of hepatocyte-Srebf-2-/- mice compared to controls. The cholesterol biosynthetic intermediate, desmosterol, has been previously identified as an LXR ligand (Yang et al., 2006); however, the concentration of this intermediate was actually higher in hepatocyte-Srebf-2-/- livers. Other reported ligands of LXR include: 20(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(S),25-epoxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol (Huang, 2014; Yang et al., 2006). Of these ligands, 20(S)-hydroxycholesterol and 22(R)-hydroxycholesterol were not detected and concentrations of 24(S)-hydroxycholesterol, 24(S),25-epoxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol. 20(S)-hydroxycholesterol and 22(R)-hydroxycholesterol were either not consistently changed or slightly higher in hepatocyte-Srebf-2-/- livers compared to controls, suggesting that the missing SREBP-2-dependent endogenous LXR ligand is not one previously identified (Supplementary file 1). In addition to LXR, Srebf-1c is transcriptionally activated by insulin, which is stimulated by feeding mice a high carbohydrate diet (Horton et al., 1998; Shimomura et al., 1999). To determine whether insulin-mediated activation of SREBP-1c was intact in hepatocyte-Srebf-2-/- livers, we subjected mice to a fasting/refeeding protocol using a high carbohydrate/low fat diet previously shown to induce SREBP-1c expression (Horton et al., 1998) (Table 2). In the fasted state, SREBP-1c levels are extremely low. As shown in Table 3, refeeding the high carbohydrate diet to fasted WT mice increased the expression of SREBP-1c mRNA in WT mice by 41-fold. In contrast, the SREBP-1c mRNA levels in livers from refed hepatocyte-Srebf-2-/- mice only increased to a level that was slightly higher than fasted WT mice. There were also blunted increases in the expression of FA synthesis genes in hepatocyte-Srebf-2-/- livers. The increase in FA synthesis mRNA expression that remained was likely mediated by ChREBP, a glucose-responsive transcription factor that can independently activate these genes (Ishii et al., 2004). These studies confirm that insulin-mediated induction of SREBP-1c requires intact LXR activity. Table 2 Phenotypic parameters in fasted and refed WT and hepatocyte-Srebf-2-/- mice. Male mice 9–12 wks of age were subjected to fasting and refeeding as described in 'Materials and methods.' Each value represents the mean ± SEM. https://doi.org/10.7554/eLife.25015.009 ParameterWTSrebf-2-/-FastedRefedFastedRefedNumber6666Body weight (g)22.7 ± 1.425.8 ± 1.119.0 ± 1.321.7 ± 1.2*Liver weight (g)0.92 ± 0.071.53 ± 0.190.82 ± 0.101.23 ± 0.13Liver cholesterol (mg/g)1.80 ± 0.081.02 ± 0.031.03 ± 0.05*0.71 ± 0.07*Liver triglycerides (mg/g)52.6 ± 1110.3 ± 1.833.2 ± 4.83.0 ± 0.5*Plasma cholesterol (mg/dl)142 ± 9.090.2 ± 1563.3 ± 7.3*43.6 ± 6.1*Plasma triglyceride (mg/dl)142 ± 11122 ± 1658.5 ± 4.6*28.9 ± 3.8*Plasma insulin (ng/ml)0.07 ± 0.011.00 ± 0.300.08 ± 0.020.48 ± 0.17Plasma glucose (mg/dl)184 ± 28220 ± 14121 ± 14182 ± 16 * denotes a level of statistical significance of p<0.05 (Student's t test) between WT and hepatocyte-Srebf-2 -/- mice. Table 3 Gene expression in the livers of fasted and refed WT and hepatocyte-Srebf-2-/- mice. Total RNA from livers of each mouse liver described in Table 2 was subjected to real-time RT-PCR as described in 'Materials and methods.' ApoB was used as the invariant control mRNA. Each value represents the amount of mRNA relative to that in fasted WT mice, which is arbitrarily defined as 1. https://doi.org/10.7554/eLife.25015.010 WTSrebf-2-/-FastedRefedFastedRefedSREBP PathwaySREBP-21.0 ± 0.11.4 ± 0.10.1 ± 0.00.5 ± 0.1SREBP-1a1.0 ± 0.12.6 ± 0.31.2 ± 0.14.7 ± 1.2SREBP-1c1.0 ± 0.141 ± 2.00.2 ± 0.02.7 ± 1.5Cholesterol MetabolismLDLR1.0 ± 0.03.0 ± 0.21.0 ± 0.12.3 ± 0.2HMG-CoA synthase1.0 ± 0.111 ± 1.80.7 ± 0.12.7 ± 0.8HMG-CoA reductase1.0 ± 0.011 ± 1.21.0 ± 0.14.1 ± 0.8Squalene synthase1.0 ± 0.14.3 ± 0.50.8 ± 0.11.1 ± 0.2Fatty Acid MetabolismAcetyl-CoA Carboxylase11.0 ± 0.118 ± 2.30.7 ± 0.06.9 ± 1.4Fatty acid synthase1.0 ± 0.192 ± 7.60.4 ± 0.016 ± 6.0ELOVL61.0 ± 0.155 ± 7.40.7 ± 0.110 ± 2.8Stearoyl-CoA desaturase 11.1 ± 0.231 ± 5.40.0 ± 0.01.8 ± 1.0PNPLA31.3 ± 0.5211 ± 431.9 ± 0.329 ± 7.8CHREBP1.0 ± 0.13.4 ± 0.20.7 ± 0.01.4 ± 0.2Glucose MetabolismGlucokinase1.2 ± 0.351 ± 3.31.8 ± 0.317 ± 3.2G6PD1.0 ± 0.110 ± 2.12.6 ± 0.48.4 ± 3.2PEPCK1.0 ± 0.10.0 ± 0.01.1 ± 0.10.1 ± 0.0ControlApoB1.0 ± 0.10.9 ± 0.01.0 ± 0.10.9 ± 0.1 Deletion of SREBP-2 in the liver reduced the amount of LDLR mRNA by ~20% but there was an accompanying ~80% reduction in the mRNA level of PCSK9 (Figure 2A). PCSK9 is a secreted protein that degrades LDLRs in liver (Lagace et al., 2006). In livers of hepatocyte-Srebf-2-/- mice, the reduction in LDLR production was balanced by the reduction in PCSK9-mediated LDLR destruction, which ultimately led to no measurable change in steady-state LDLR protein levels (data not shown). Nevertheless, plasma cholesterol levels in hepatocyte-Srebf-2-/- mice were still 50% lower than those measured in WT mice (Table 1). To determine whether lower plasma cholesterol levels were a result of increased clearance of apoB-containing lipoproteins, we measured the 125I-labeled LDL clearance. LDL was isolated from LDL receptor knockout mice and labeled the apoB with 125I (Horton et al., 1999). As shown in Figure 6A, the clearance of LDL was identical in WT and hepatocyte-Srebf-2-/- mice. Therefore, the lower plasma and TG concentrations were likely a result of reduced VLDL production; therefore we measured rates of TG secretion in mice following the administration of Triton. As shown in Figure 6B and C, TG secretion rates from livers of hepatocyte-Srebf-2-/- mice reduced by 29%. Figure 6 Download asset Open asset In vivo VLDL secretion and LDL clearance in WT and hepatocyte-Srebf-2-/- mice. (A) Eleven male mice (8 weeks of age) of each genotype were subjected to i.v. injection of 125I-labeled LDL (15 µg of protein, 496 cpm/ng protein). Blood was obtained at 30 s (time 0) and 10, 30, 60, 120, and 240 min for the quantification of plasma content of 125I-labeled apoB. Data were plotted as the percentage of 0 time value. (B) Five male mice (8 wks of age) of each genotype were fasted for 4 hr prior to the study. Each mouse was injected i.v. with 10% triton-saline solution at 500 mg/kg. Plasma TG accumulation of each mouse at 0, 0.5, 1, and 2 hr after the triton injection were measured. (C) Plasma TG secretion rate during a detergent block of lipolysis was calculated for each mouse from the linear regression analysis of the time vs. TG concentration. https://doi.org/10.7554/eLife.25015.011 Discussion The current data confirm that SREBP-2 is the primary transcriptional regulator of cholesterol biosynthesis in vivo. Deletion of Srebf-2 in hepatocytes reduced the expression of all cholesterol biosynthetic genes and rates of hepatic cholesterol synthesis. Despite the deficiency in liver cholesterol content, no apparent additional mechanisms are present in the livers capable of restoring cholesterol levels to normal in the absence of SREBP-2. The unexpected finding in Srebf-2 knockout livers was the marked reduction of SREBP-1c expression and genes involved in FA synthesis. While this manuscript was in preparation, Vergnes et al. (Vergnes et al., 2016) also reported that SREBP-1c expression and its regulated genes were reduced in livers of SREBP-2 hypomorphic mice. Here, dietary supplementation of cholesterol or an LXR agonist restored SREBP-1c expression and the mRNAs encoding the FA biosynthetic enzymes, which suggests that the loss of flux through the cholesterol biosynthetic pathway results in the loss of an endogenous LXR ligand required for normal LXR activity. The current studies also have identified the first molecular mechanism linking cholesterol and FA synthesis in liver. This link requires SREBP-2 expression and is apparently supplied by an intermediate or product of cholesterol biosynthesis that serves as a ligand for LXR, which is required for SREBP-1c expression. Coupling cholesterol and FA synthesis may be important for the efficient esterification of cholesterol since oleic acid is the preferred substrate for the cholesterol esterifying enzyme ACAT (Yang et al., 1997). Cholesterol may also be required for the normal formation of the VLDL particle lipid core and thus linking cholesterol and FA synthesis might be necessary for efficient VLDL production by the liver. LXR can be activated by 20(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S)-hydroxycholesterol, 24(S),25-epoxycholesterol, 25-hydroxycholesterol, and 27-hydroxycholesterol as well as the cholesterol biosynthetic intermediate desmosterol (Huang, 2014; Yang et al., 2006). Supplementation of a synthetic LXR ligand or feeding cholesterol were both capable of restoring the SREBP-1c expression indicating that LXR was present and that if a ligand was provided it was capable of normally activating Srebf-1c transcription in the SREBP-2 deficient mice. However, we were unable to identify any changes in concentrations of known LXR ligands hepatocyte-Srebf-2-/- liver, indicating that the missing ligand is unique and not previously identified. Further studies will be required to identify this endogenous ligand. The phenotype that resulted from the deletion of Srebf-2 in hepatocytes was nearly indistinguishable from mice that lack Scap in hepatocytes (Matsuda et al., 2001; Moon et al., 2012). The only molecular signature we found that differed between hepatocyte-Srebf-2-/- and hepatocyte-Scap-/- livers was the retained expression of SREBP-1a and ACC2 in the livers of hepatocyte-Srebf-2-/- mice. These studies confirm that SREBP-1a has only a minor role in regulating basal and stimulated cholesterol and fatty acid synthesis in the liver. The phenotypic similarities between hepatocyte-Srebf-2-/- and hepatocyte-Scap-/- mice also suggest that blocking SREBP-2 action would be effective in preventing the development of hepatic steatosis in mice with insulin resistance and/or diabetes. The markedly reduced expression of lipogenic genes in hepatocyte-Srebf-2-/- livers and the blunted response of these genes to refeeding a high carbohydrate diet suggest that blocking SREBP-2 action would also be effective in preventing the development of hepatic steatosis induced by hyperinsulinemia, similar to the results obtained in Scap deficient mice that also lack leptin (Moon et al., 2012). Plasma cholesterol and TG concentrations were also significantly lower in hepatocyte-Srebf-2-/- mice. The LDLR protein level was not reduced in hepatocyte-Srebf-2-/- livers despite a 20% reduction in LDLR mRNA levels; however, the mRNA levels of PCSK9 were reduced by 80% in hepatocyte-Srebf-2-/- livers. Inasmuch as LDL clearance was not altered in hepatocyte-Srebf-2-/- mice, the reduced LDLR protein destruction by PCSK9 likely offset the reduced LDLR production since LDL clearance from the plasma of hepatocyte-Srebf-2-/- mice was not lower. Thus, the lower plasma lipid levels were a reflection of reduced VLDL secretion from the liver. A potential additional benefit of inhibiting SREBP expression in the liver, independent of the reduction in hepatic TGs, is the reduced expression of PNPLA3. Polymorphisms in PNPLA3 are associated with hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma in humans (Romeo et al., 2008; Speliotes et al., 2010). SREBP-1c is the only known transcriptional activator of PNPLA3 expression (Huang et al., 2010). In WT mice refed a high carbohydrate diet, PNPLA3 mRNA levels increased >200–fold above the fasted state, whereas in livers of hepatocyte-Srebf-2-/- mice PNPLA3 only increased 15–fold (Table 3). The blunted PNPLA3 expression in livers of hepatocyte-Srebf-2-/- mice was likely due to the accompanying loss of SREBP-1c since feeding the hepatocyte-Srebf-2-/- mice diets supplemented with an LXR agonist or cholesterol (data not shown) restored SREBP-1c and PNPLA3 expression. Studies by Hobbs and colleagues (Li et al., 2012; Smagris et al., 2015) previously demonstrated that high expression levels of the mutant PNPLA3 protein are required for the development of hepatic steatosis in mice. Thus, a reduction in mutant PNPLA3 expression as a result of inhibiting SREBP-2 or Scap may be of therapeutic benefit in individuals who carry the PNPLA3 polymorphism. The current report represents the last in a series of studies that we have carried out using genetically manipulated mice to elucidate the in vivo function of the SREBP family members (Horton et al., 2002). They confirm that SREBP-2 mediates the regulated expression of cholesterol biosynthetic genes and also controls steady-state tissue cholesterol concentrations by simultaneously regulating cholesterol synthesis and uptake from plasma and by modulating the expression of the LDLR and PCSK9. The physiological changes that result from deleting Srebf-2 mirror that of mice that lack Scap in hepatocytes since we show that SREBP-2 expression is required to produce an LXR ligand required for normal SREBP-1c expression. The resulting phenotypes suggest that the inhibition of SREBP-2 or Scap in the liver, wh
The synthesis of fatty acids and cholesterol, the building blocks of membranes, is regulated by three membrane-bound transcription factors: sterol regulatory element-binding proteins (SREBP)-1a, -1c, and -2. Their function in liver has been characterized in transgenic mice that overexpress each SREBP isoform and in mice that lack all three nuclear SREBPs as a result of gene knockout of SREBP cleavage-activating protein (SCAP), a protein required for nuclear localization of SREBPs. Here, we use oligonucleotide arrays hybridized with RNA from livers of three lines of mice (transgenic for SREBP-1a, transgenic for SREBP-2, and knockout for SCAP) to identify genes that are likely to be direct targets of SREBPs in liver. A total of 1,003 genes showed statistically significant increased expression in livers of transgenic SREBP-1a mice, 505 increased in livers of transgenic SREBP-2 mice, and 343 showed decreased expression in Scap-/- livers. A subset of 33 genes met the stringent combinatorial criteria of induction in both SREBP transgenics and decreased expression in SCAP-deficient mice. Of these 33 genes, 13 were previously identified as direct targets of SREBP action. Of the remaining 20 genes, 13 encode enzymes or carrier proteins involved in cholesterol metabolism, 3 participate in fatty acid metabolism, and 4 have no known connection to lipid metabolism. Through application of stringent combinatorial criteria, the transgenic/knockout approach allows identification of genes whose activities are likely to be controlled directly by one family of transcription factors, in this case the SREBPs.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of the proteinase K subfamily of subtilases that reduces the number of LDL receptors (LDLRs) in liver through an undefined posttranscriptional mechanism. We show that purified PCSK9 added to the medium of HepG2 cells reduces the number of cell-surface LDLRs in a dose- and time-dependent manner. This activity was approximately 10-fold greater for a gain-of-function mutant, PCSK9(D374Y), that causes hypercholesterolemia. Binding and uptake of PCSK9 were largely dependent on the presence of LDLRs. Coimmunoprecipitation and ligand blotting studies indicated that PCSK9 and LDLR directly associate; both proteins colocalized to late endocytic compartments. Purified PCSK9 had no effect on cell-surface LDLRs in hepatocytes lacking autosomal recessive hypercholesterolemia (ARH), an adaptor protein required for endocytosis of the receptor. Transgenic mice overexpressing human PCSK9 in liver secreted large amounts of the protein into plasma, which increased plasma LDL cholesterol concentrations to levels similar to those of LDLR-knockout mice. To determine whether PCSK9 was active in plasma, transgenic PCSK9 mice were parabiosed with wild-type littermates. After parabiosis, secreted PCSK9 was transferred to the circulation of wild-type mice and reduced the number of hepatic LDLRs to nearly undetectable levels. We conclude that secreted PCSK9 associates with the LDLR and reduces hepatic LDLR protein levels.
PCSK9 encodes proprotein convertase subtilisin/kexin type 9a (PCSK9), a member of the proteinase K subfamily of subtilases. Missense mutations in PCSK9 cause an autosomal dominant form of hypercholesterolemia in humans, likely due to a gain-of-function mechanism because overexpression of either WT or mutant PCSK9 reduces hepatic LDL receptor protein (LDLR) in mice. Here, we show that livers of knockout mice lacking PCSK9 manifest increased LDLR protein but not mRNA. Increased LDLR protein led to increased clearance of circulating lipoproteins and decreased plasma cholesterol levels (46 mg/dl in Pcsk9 –/– mice versus 96 mg/dl in WT mice). Statins, a class of drugs that inhibit cholesterol synthesis, increase expression of sterol regulatory element-binding protein-2 (SREBP-2), a transcription factor that activates both the Ldlr and Pcsk9 genes. Statin administration to Pcsk9 –/– mice produced an exaggerated increase in LDLRs in liver and enhanced LDL clearance from plasma. These data demonstrate that PCSK9 regulates the amount of LDLR protein in liver and suggest that inhibitors of PCSK9 may act synergistically with statins to enhance LDLRs and reduce plasma cholesterol.
